Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RTRX - Retrophin Inc.

Previous close
24.25
24.250   100.000%

Share volume: 378,991
Last Updated: Wed 18 Nov 2020 10:00:01 PM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 50%
Dept financing 44%
Liquidity 30%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$24.25
P/E Ratio 
N/A
DAY RANGE
$24.25 - $24.25
EPS 
-$1.71
52 WEEK RANGE
$8.98 - $24.96
52 WEEK CHANGE
$86.25
MARKET CAP 
1.238 B
YIELD 
N/A
SHARES OUTSTANDING 
51.052 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$50,367,706
AVERAGE 10 VOLUME 
$386,878
AVERAGE 30 VOLUME 
$295,781
Company detail
CEO: Eric Dube
Region: US
Website: http://www.retrophin.com
Employees: 221
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Recent news